Sanofi is in the midst of building out a new blood disorder franchise after completing its acquisition of Bioverativ Inc. in 2018 and launching the rare blood disease treatment Cablivi this year. The business area is expected to be a big growth driver for the company, but it’s also a competitive field that Sanofi will have to navigate.
Sanofi Genzyme exec VP Bill Sibold talked to Scrip in an interview in New York on 14 May about building a new franchise, the launch of Cablivi (caplacizumab-yhdp) for acquired thrombotic thrombocytopenic purpura (aTTP),
